InxMed
InxMed is a Shanghai biotechnology company developing IN10018 (ifebemtinib), a focal adhesion kinase inhibitor, which is in a phase 3 trial with the KRAS G12C inhibitor garsorasib against standard therapy in KRAS G12C-mutant lung cancer.
Overview
InxMed, based in Shanghai, develops drugs against the tumour microenvironment and drug resistance. Its lead candidate IN10018 (ifebemtinib) inhibits focal adhesion kinase (FAK), a signal that helps tumours resist KRAS inhibitors and chemotherapy, and is being tested in a phase 3 trial combined with the KRAS G12C inhibitor D-1553 (garsorasib) against standard therapy in non-small-cell lung cancer, as well as in platinum-resistant ovarian cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Scorecard
All companies- phase 3 +3
- modalities +2
- registry trials +7
Similar pages
not linked directly; found by shared links- CompanyInxMed (Shanghai)
Shares A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation, IN10018, Ovarian cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyNanjing Leads Biolabs
Shares Ovarian cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyHaihe Biopharma
Shares Ovarian cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyBioInvent International
Shares Ovarian cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyShenzhen Ionova Life Sciences
Shares Ovarian cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyGenelux
Shares Ovarian cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyAvistone Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMaia Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.